Vaxil Bio Company Description

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer.

The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma.

It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.

Vaxil Bio Ltd.

Country	Canada
Founded	2006
Industry	Biotechnology
Sector	Healthcare
CEO	Gadi Levin

Contact Details

Address: 559 Briar Hill Avenue Toronto, Ontario M5N 1N1 Canada
Phone	647-558-5564
Website	vaxil-bio.com

Stock Details

Ticker Symbol	VXL
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA92243L1076
SIC Code	2836

Key Executives

Name	Position
Gadi Levin B.Com., C.A., CPA, M.B.A.	Chief Executive Officer and Chairman
Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA	Chief Financial Officer
Dr. Riva Kovjazin M.D.	Senior Scientist and Member of Scientific Advisory Board